The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder
{"title":"The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder","authors":"Pankaj V. Jariwala , Dilip Gude","doi":"10.1016/j.ihjccr.2022.11.004","DOIUrl":null,"url":null,"abstract":"<div><p>Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the <strong><em>Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study</em></strong> to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.</p></div>","PeriodicalId":100653,"journal":{"name":"IHJ Cardiovascular Case Reports (CVCR)","volume":"6 4","pages":"Pages 158-162"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676/pdfft?md5=05e1725620d2b1c3c90a8adaf2b4cdf4&pid=1-s2.0-S2468600X22000676-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IHJ Cardiovascular Case Reports (CVCR)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
